Literature DB >> 25550797

Prognostic value of immune cell infiltration, tertiary lymphoid structures and PD-L1 expression in Merkel cell carcinomas.

Daniel S Behr1, Wiebke K Peitsch1, Christian Hametner2, Felix Lasitschka3, Roland Houben4, Kathrin Schönhaar1, Julia Michel1, Claudia Dollt1, Matthias Goebeler4, Alexander Marx5, Sergij Goerdt1, Astrid Schmieder1.   

Abstract

Merkel cell carcinoma (MCC) is an aggressive, virus-associated, neuroendocrine tumor of the skin mainly affecting immunocompromised patients. Higher intratumoral infiltration with CD3 and CD8 positive T-cells is associated with a better prognosis, highlighting the relevance of the immune system for MCC development and progression. In this study 21 primary MCCs were stained with immune cell markers including CD3, CD4, CD8, CD68, CD20, and S100. Furthermore, tumor-infiltrating neutrophils, tertiary lymphoid structures and PD-L1 expression were analyzed and correlated with overall and recurrence free survival. All MCCs were Merkel Cell Polyomavirus positive. Overall and recurrence-free survival did not correlate with intra- and peritumoral CD3 and CD8 T-cell infiltration. In addition, no significant association regarding prognosis was found for tumor-associated neutrophils, tumor-associated macrophages or PD-L1 positivity in MCCs. Interestingly, the presence of tertiary lymphoid structures (TLS) in the tumor microenvironment significantly correlated with recurrence-free survival (P=0.025). In addition, TLS were significantly associated with a higher CD8/CD4 ratio in the tumor periphery (P=0.032), but not in the center of the tumor (P > 0.999). These results demonstrate for the first time that TLS, easily assessed in paraffin-embedded tissue in the tumor periphery of MCCs, may be a valuable prognostic factor indicating prolonged recurrence free survival.

Entities:  

Keywords:  Merkel cell carcinoma; PD-L1; immune cell infiltration; tertiary lymphoid structures

Mesh:

Substances:

Year:  2014        PMID: 25550797      PMCID: PMC4270630     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  49 in total

1.  Short German guidelines: Merkel cell carcinoma.

Authors:  Jürgen Becker; Cornelia Mauch; Rolf-Dieter Kortmann; Ulrich Keilholz; Friedrich Bootz; Claus Garbe; Axel Hauschild; Ingrid Moll
Journal:  J Dtsch Dermatol Ges       Date:  2008-05       Impact factor: 5.584

2.  Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures.

Authors:  Marie-Caroline Dieu-Nosjean; Martine Antoine; Claire Danel; Didier Heudes; Marie Wislez; Virginie Poulot; Nathalie Rabbe; Ludivine Laurans; Eric Tartour; Luc de Chaisemartin; Serge Lebecque; Wolf-Herman Fridman; Jacques Cadranel
Journal:  J Clin Oncol       Date:  2008-09-20       Impact factor: 44.544

3.  Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens.

Authors:  Roland Houben; Masahiro Shuda; Rita Weinkam; David Schrama; Huichen Feng; Yuan Chang; Patrick S Moore; Jürgen C Becker
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

4.  Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival.

Authors:  Kelly G Paulson; Jayasri G Iyer; Andrew R Tegeder; Renee Thibodeau; Janell Schelter; Shinichi Koba; David Schrama; William T Simonson; Bianca D Lemos; David R Byrd; David M Koelle; Denise A Galloway; J Helen Leonard; Margaret M Madeleine; Zsolt B Argenyi; Mary L Disis; Juergen C Becker; Michele A Cleary; Paul Nghiem
Journal:  J Clin Oncol       Date:  2011-03-21       Impact factor: 44.544

5.  High levels of antibodies against merkel cell polyomavirus identify a subset of patients with merkel cell carcinoma with better clinical outcome.

Authors:  Antoine Touzé; Emmanuelle Le Bidre; Hélène Laude; Maxime J J Fleury; Raphaël Cazal; Françoise Arnold; Agnès Carlotti; Eve Maubec; François Aubin; Marie-Françoise Avril; Flore Rozenberg; Mauro Tognon; Annabel Maruani; Serge Guyetant; Gérard Lorette; Pierre Coursaget
Journal:  J Clin Oncol       Date:  2011-03-21       Impact factor: 44.544

6.  Tumor infiltrating immune cells and outcome of Merkel cell carcinoma: a population-based study.

Authors:  Harri Sihto; Tom Böhling; Heli Kavola; Virve Koljonen; Marko Salmi; Sirpa Jalkanen; Heikki Joensuu
Journal:  Clin Cancer Res       Date:  2012-03-30       Impact factor: 12.531

7.  Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells.

Authors:  Jérémy Goc; Claire Germain; Thi Kim Duy Vo-Bourgais; Audrey Lupo; Christophe Klein; Samantha Knockaert; Luc de Chaisemartin; Hanane Ouakrim; Etienne Becht; Marco Alifano; Pierre Validire; Romain Remark; Scott A Hammond; Isabelle Cremer; Diane Damotte; Wolf-Herman Fridman; Catherine Sautès-Fridman; Marie-Caroline Dieu-Nosjean
Journal:  Cancer Res       Date:  2013-12-23       Impact factor: 12.701

Review 8.  Common and unique features of T antigens encoded by the polyomavirus group.

Authors:  J M Pipas
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

Review 9.  CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.

Authors:  Patrick A Ott; F Stephen Hodi; Caroline Robert
Journal:  Clin Cancer Res       Date:  2013-10-01       Impact factor: 12.531

10.  Role of Tertiary Lymphoid Structures (TLS) in Anti-Tumor Immunity: Potential Tumor-Induced Cytokines/Chemokines that Regulate TLS Formation in Epithelial-Derived Cancers.

Authors:  Erica M Pimenta; Betsy J Barnes
Journal:  Cancers (Basel)       Date:  2014-04-23       Impact factor: 6.639

View more
  29 in total

Review 1.  Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity.

Authors:  Victor H Engelhard; Anthony B Rodriguez; Ileana S Mauldin; Amber N Woods; J David Peske; Craig L Slingluff
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

2.  Merkel cell carcinoma masquerading as cellulitis: a case report and review of the literature.

Authors:  F Safa; M Pant; C Weerasinghe; R Felix; T Terjanian
Journal:  Curr Oncol       Date:  2018-02-28       Impact factor: 3.677

3.  Prognostic Impact of MCPyV and TIL Subtyping in Merkel Cell Carcinoma: Evidence from a Large European Cohort of 95 Patients.

Authors:  C Ricci; A Righi; F Ambrosi; D Gibertoni; F Maletta; S Uccella; F Sessa; S Asioli; M Pellilli; R Maragliano; S La Rosa; M G Papotti; S Asioli
Journal:  Endocr Pathol       Date:  2020-03       Impact factor: 3.943

4.  Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.

Authors:  Paul Nghiem; Shailender Bhatia; Evan J Lipson; William H Sharfman; Ragini R Kudchadkar; Andrew S Brohl; Phillip A Friedlander; Adil Daud; Harriet M Kluger; Sunil A Reddy; Brian C Boulmay; Adam I Riker; Melissa A Burgess; Brent A Hanks; Thomas Olencki; Kim Margolin; Lisa M Lundgren; Abha Soni; Nirasha Ramchurren; Candice Church; Song Y Park; Michi M Shinohara; Bob Salim; Janis M Taube; Steven R Bird; Nageatte Ibrahim; Steven P Fling; Blanca Homet Moreno; Elad Sharon; Martin A Cheever; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2019-02-06       Impact factor: 44.544

Review 5.  Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches.

Authors:  Daniela Femia; Natalie Prinzi; Andrea Anichini; Roberta Mortarini; Federico Nichetti; Francesca Corti; Martina Torchio; Giorgia Peverelli; Filippo Pagani; Andrea Maurichi; Ilaria Mattavelli; Massimo Milione; Nice Bedini; Ambra Corti; Maria Di Bartolomeo; Filippo de Braud; Sara Pusceddu
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

6.  Intratumoral accumulation of podoplanin-expressing lymph node stromal cells promote tumor growth through elimination of CD4+ tumor-infiltrating lymphocytes.

Authors:  Aikaterini Hatzioannou; Saba Nayar; Anastasios Gaitanis; Francesca Barone; Constantinos Anagnostopoulos; Panayotis Verginis
Journal:  Oncoimmunology       Date:  2016-07-29       Impact factor: 8.110

7.  Identification and Characterization of Tertiary Lymphoid Structures in Murine Melanoma.

Authors:  Anthony B Rodriguez; J David Peske; Victor H Engelhard
Journal:  Methods Mol Biol       Date:  2018

Review 8.  Therapeutic Lymphoid Organogenesis in the Tumor Microenvironment.

Authors:  Aliyah M Weinstein; Walter J Storkus
Journal:  Adv Cancer Res       Date:  2015-05-05       Impact factor: 6.242

9.  PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

Authors:  Paul T Nghiem; Shailender Bhatia; Evan J Lipson; Ragini R Kudchadkar; Natalie J Miller; Lakshmanan Annamalai; Sneha Berry; Elliot K Chartash; Adil Daud; Steven P Fling; Philip A Friedlander; Harriet M Kluger; Holbrook E Kohrt; Lisa Lundgren; Kim Margolin; Alan Mitchell; Thomas Olencki; Drew M Pardoll; Sunil A Reddy; Erica M Shantha; William H Sharfman; Elad Sharon; Lynn R Shemanski; Michi M Shinohara; Joel C Sunshine; Janis M Taube; John A Thompson; Steven M Townson; Jennifer H Yearley; Suzanne L Topalian; Martin A Cheever
Journal:  N Engl J Med       Date:  2016-04-19       Impact factor: 91.245

Review 10.  Polyomavirus-driven Merkel cell carcinoma: Prospects for therapeutic vaccine development.

Authors:  Shira Tabachnick-Cherny; Thomas Pulliam; Candice Church; David M Koelle; Paul Nghiem
Journal:  Mol Carcinog       Date:  2020-03-27       Impact factor: 4.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.